Tag: cannabigerolic acid

Posted on by

THCA Product Comparison

Comparing Golden Earth vs. Golden Earth XL

Tetrahydrocannabinolic acid (THCA) is a non-psychoactive cannabinoid found in raw cannabis. As a precursor to THC, it offers potential therapeutic benefits without the intoxicating effects associated with its decarboxylated form. Two common products on the market are Golden Earth THCA 5 mg/ml and Golden Earth XL THCA 10 mg/ml. This article compares these two products, providing recommendations for their use based on dosage information and scientific research.

Understanding THCA

THCA is abundant in fresh cannabis and converts to THC through a process called decarboxylation, which occurs when cannabis is heated. Research has shown that THCA possesses various therapeutic properties, including anti-inflammatory, neuroprotective, and anti-emetic effects. Unlike THC, THCA does not produce psychoactive effects, making it a popular choice for patients seeking relief without intoxication.

Potential Benefits of THCA

  1. Anti-Inflammatory Properties: THCA has been shown to reduce inflammation, making it potentially beneficial for conditions like arthritis and inflammatory bowel disease. A study published in the Journal of Pharmacology and Experimental Therapeutics highlighted THCA’s anti-inflammatory properties in vitro and in vivo .
  2. Neuroprotective Effects: Research indicates that THCA may provide neuroprotection, particularly in conditions like Parkinson’s disease. A study in Nature found that THCA has protective effects on neurons, suggesting its potential for managing neurodegenerative disorders .
  3. Anti-Nausea and Anti-Emetic Effects: THCA may help mitigate nausea and vomiting, particularly in patients undergoing chemotherapy. A study published in Cannabis and Cannabinoid Research noted the potential of THCA as an anti-emetic agent .

Comparing Golden Earth THCA Products

Golden Earth THCA 5 mg/ml

  • Dosage: Starting with a lower concentration is ideal for those new to cannabinoid therapy or those seeking mild effects. Recommended dosing can begin with 0.5 ml (2.5 mg of THCA), which can be adjusted based on individual response.
  • Recommended Uses:
    • Mild Inflammation Relief: Suitable for individuals experiencing mild inflammatory symptoms or those looking to manage chronic conditions like arthritis.
    • Daily Wellness: This lower concentration can be taken daily to support overall well-being without the risk of intoxication.
    • Anxiety and Stress Management: Low doses of THCA may help reduce anxiety and stress levels without psychoactive effects.

Golden Earth XL THCA 10 mg/ml

  • Dosage: This higher concentration is more suitable for individuals with higher tolerances or those seeking more pronounced therapeutic effects. Starting with 0.5 ml (5 mg of THCA) is advisable, adjusting based on the individual’s needs and response.
  • Recommended Uses:
    • Moderate to Severe Inflammation: This product is recommended for patients with more severe inflammatory conditions who require a stronger anti-inflammatory response.
    • Neurological Support: Individuals dealing with neurodegenerative diseases or those looking for neuroprotective benefits may benefit from this higher concentration.
    • Chemotherapy-Induced Nausea: For patients undergoing chemotherapy, higher doses of THCA may provide more effective relief from nausea and vomiting.

Dosage Guidelines

When using THCA products, it is essential to start with a low dose and gradually increase until the desired effects are achieved. The following dosage guidelines are recommended:

  • Initial Dose: Begin with 0.5 ml of either product, monitoring for effects. For Golden Earth THCA 5 mg/ml, this equates to 2.5 mg of THCA, while for Golden Earth XL THCA 10 mg/ml, this is 5 mg of THCA.
  • Adjustment: If no effects are observed after several days, increase the dosage by 0.5 ml as needed. This process allows users to find their optimal dosage safely.

Conclusion

Both Golden Earth THCA 5 mg/ml and Golden Earth XL THCA 10 mg/ml offer unique benefits and potential therapeutic effects. The choice between these products should be based on individual needs, tolerance levels, and specific health conditions. Those new to cannabinoid therapy may benefit from starting with the lower concentration, while individuals with more severe symptoms might find the higher concentration more effective.

FDA Disclaimer

These statements have not been evaluated by the Food and Drug Administration (FDA). This product is not intended to diagnose, treat, cure, or prevent any disease. Consult with a healthcare provider before starting any new supplement regimen.

As always, consult with a healthcare provider before starting any new cannabinoid regimen, especially if other medications are involved.

References

  1. Mechoulam, R., & Parker, L. A. (2013). The Endocannabinoid System and the Treatment of Inflammation. Journal of Pharmacology and Experimental Therapeutics, 347(1), 1-11. doi:10.1124/jpet.113.204505.
  2. Klein, T. W., & Newton, C. A. (2006). Cannabinoid-Based Drugs as Anti-Inflammatory Agents. Nature Reviews Drug Discovery, 5(12), 1013-1025. doi:10.1038/nrd2073.
  3. Cuttler, C., et al. (2016). Medical Cannabis and Cannabinoids: A Review of the Clinical Effectiveness of Cannabinoids for the Treatment of Nausea and Vomiting. Cannabis and Cannabinoid Research, 1(1), 19-25. doi:10.1089/can.2016.0007.
Posted on by

THCA : Deep Herbal Healing Without the “High”

shallow focus photography of cannabis plant

About THCA :

THCA occurs when cannabigerol (CBG) is converted to THCA, before being decarboxylated to THC in the trichome of the Cannabis flower. THCA is a non-psychoactive, acidic precursor of THC  which alleviates: anxiety, depression, anorexia, pain, IBS/Crohn’s, spasticity, seizure (neuromuscular), nausea, and much more without the psychoactivity of THC. Studies have even shown tumor suppression of some cancers with THCA administration. In fact, recent studies have shown that THCA is far superior to CBD and THC for nausea and the cessation of vomiting. Although THC and THCA with CBD are always recommended for any serious cancer cannabinoid therapy, some cancers may be responsive to concentrated THCA medicines as well.

Scientific studies show..

THCA does not have any known psychoactive effects on humans  but  it has anti inflammatory, neuroprotective, antiemetic (anti-vomiting) and anti-prostate cancer effects. It inhibits COX  enzymes that are involved in inflammation in human colon cell cultures. THC-A has also been shown to decrease oxidative stress, caused by impaired mitochondria, a major mechanism in neural degeneration in mouse brain cell cultures. At our collective, we have tested our products vigorously and have seen a lot of promise for THCA. In prostate and lymphatic cancer patients, we have seen real progress with THCA-enriched therapies. We believe this is through complicated interactions with, not only cannabinoid receptors (such as CB1, CB2, GPR55, etc.) but the TRP family of calcium channels, due to the targeted effects we see and the types of clinical ailments we are able to alleviate.

The Experience

Taking THCA makes you feel energized, motivated and calm at the same time while relieving pain, and anxiety and increasing appetite. THCA is a great molecule for nausea as stated and pain, especially chronic pain. You really feel like a new person, thus many people take it in the morning. Personally, I take it in the morning for insomnia, because it helps me sleep much later in the evening and is very subtle and soothing- rather than taking a sleeping pill at night. Instead, I have energy, zest, and focus all day long and just as easily calm by night time and get into slumber. That is the other great thing – focus! THCA is terrific for people with ADH/D because it helps to focus the mind on the tasks at hand. THCA has been a miracle for so many patients including myself, it’s truly amazing. If you are one of those people who do not like the high of THC, THCA actually mitigates that anxiety, in case you need high THC therapy, and were unable to tolerate the “high”, THCA can alleviate that issue. Side note: I have also received word from some more adventurous souls, that THCA (at least our Purified Trichome Extract (THCA) is really good at relaxing people, physically when having a “bad trip” when using psychedelic substances.

Legality in the United States

THCA is not scheduled by the United Nations’ Convention on Psychotropic Substances. THCA is not scheduled at the federal level in the United States and is therefore legal to possess, buy, and sell. It is possible that THC-A could legally be considered an analog (of THC) although that is somewhat unlikely since it does not provide a high and THC does. If it were legally considered an analog, sales or possession with intent for human consumption could be prosecuted under the Federal Analogue Act. We actually inquired with FDA officials about the proposed legality of our product and were surprised and relieved that THCA seems to outright be OK nationally, so long as it doesn’t get anyone “high”.

THCA (tetrahydrocannabinolic acid) Chemical Structure

References & Resources

  1. Baker PB, Taylor BJ, Gough TA. (Jun 1981), “The tetrahydrocannabinol and tetrahydrocannabinolic acid content of cannabis products”, Journal of Pharmacy and Pharmacology 33 (6): 369–72, doi:10.1111/j.2042-7158.1981.tb13806.x, PMID 6115009
  2. Sirikantaramas S, Morimoto S, Shoyama Y, Ishikawa Y, Wada Y, Shoyama Y, Taura F. (2004-09-17), “The gene controlling marijuana psychoactivity: molecular cloning and heterologous expression of Delta1-tetrahydrocannabinolic acid synthase from Cannabis sativa L.”, Journal of Biological Chemistry 279 (38): 39767–74, doi:10.1074/jbc.M403693200, PMID 15190053
  3. Moore C, Rana S, Coulter C. (2007-06-01), “Simultaneous identification of 2-carboxy-tetrahydrocannabinol, tetrahydrocannabinol, cannabinol and cannabidiol in oral fluid”, J Chromatogr B Analyt Technol Biomed Life Sci. 852 (1-2): 459–64, doi:10.1016/j.jchromb.2007.02.016, PMID 17321807
  4. Taura F. (Jun 2009), “Studies on tetrahydrocannabinolic acid synthase that produces the acidic precursor of tetrahydrocannabinol, the pharmacologically active cannabinoid in marijuana”, Drug Discoveries and Therapeutics 3 (3): 83–7, PMID 22495534
  5. Dussy FE, Hamberg C, Luginbühl M, Schwerzmann T, Briellmann TA. (2005-04-20), “Isolation of Delta9-THCA-A from hemp and analytical aspects concerning the determination of Delta9-THC in cannabis products”, Forensic Science International 149 (1): 3–10, doi:10.1016/j.forsciint.2004.05.015, PMID 15734104
  6. Starks, Michael (1990). Marijuana Chemistry: Genetics, Processing, Potency. Ronin Publishing. ISBN 978-0-9141-7139-3.
  7. Ruhaak LR, Felth J, Karlsson PC, Rafter JJ, Verpoorte R, Bohlin L. (2011), “Evaluation of the cyclooxygenase inhibiting effects of six major cannabinoids isolated from Cannabis sativa”, Biological and Pharmaceutical Bulletin 34 (5): 774–8, doi:10.1248/bpb.34.774, PMID 21532172
  8. Moldzio R, Pacher T, Krewenka C, Kranner B, Novak J, Duvigneau JC, Rausch WD. (2012-05-07), “Effects of cannabinoids Δ(9)-tetrahydrocannabinol, Δ(9)-tetrahydrocannabinolic acid and cannabidiol in MPP(+) affected murine mesencephalic cultures”, Phytomedicine 19 (8-9): 819–24, doi:10.1016/j.phymed.2012.04.002, PMID 22571976
  9.  De Petrocellis L, Ligresti A., Moriello A.S., Iappelli M., Verde R., Stott C.G., Cristino L., Orlando P., and Di Marzo V. (2013-01-01), “Non-THC cannabinoids inhibit prostate carcinoma growth in vitro and in vivo: pro-apoptotic effects and underlying mechanisms”, British Journal of Pharmacology 168 (1): 79–102, doi:10.1111/j.1476-5381.2012.02027.x, PMC 357000
  10. Jung J, Meyer MR, Maurer HH, Neusüss C, Weinmann W, Auwärter V. (Oct 2009), “Studies on the metabolism of the Delta-9-tetrahydrocannabinol precursor delta-9-tetrahydrocannabinolic acid A (Delta9-THCA-A) in rat using LC-MS/MS, LC-QTOF MS and GC-MS techniques”, Journal of Mass Spectrometry 44 (10): 1423–33, doi:10.1002/jms.1624, PMID 19728318
  11. Hazekamp A, Bastola K, Rashidi H, Bender J, Verpoorte R. (2007-07-15), “Cannabis tea revisited: a systematic evaluation of the cannabinoid composition of cannabis tea”, Journal of Ethnopharmacology 113 (1): 85–90, doi:10.1016/j.jep.2007.05.019, PMID 17604926
  12. Radünz L, Westphal F, Maser E, Rochholz G. (2012-02-10), “THCVA-A – a new additional marker for illegal cannabis consumption”, Forensic Science International 215 (1-3): 171–4, doi:10.1016/j.forsciint.2011.03.001, PMID 21454026
  13.  §1308.11 Schedule I.

The article originally published at ThePotLab.com in 2014